CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (8,551,000)	$ (2,997,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	21,000	23,000
Stock-based compensation expense	2,370,000	449,000
Warrant expense	0	97,000
Amortization of intangible assets	244,000	68,000
Change in fair value of warrants	2,204,000	(13,000)
Amortization of deferred financing costs	0	115,000
Amortization of convertible note discount	0	183,000
Loss on disposal of property and equipment	0	2,000
Gain on sale of patent	(750,000)	0
Change in operating assets and liabilities:
Accounts receivable	(1,000)	77,000
Prepaid expenses and other current assets	223,000	260,000
Inventory	0	36,000
Security deposits	0	180,000
Accounts payable	(78,000)	41,000
Accrued expenses	(215,000)	(299,000)
Other payables	130,000	(40,000)
Net cash used in operating activities	(3,805,000)	(1,818,000)
Cash flows from investing activities:
Release of restricted cash	1,901,000	0
Receipts from sale of patent	750,000	0
Purchase of property and equipment	(8,000)	(12,000)
Purchase of intangible assets	(89,000)	0
Net cash provided by / (used in) investing activities	2,214,000	(226,000)
Cash flows from financing activities:
Cash paid in lieu of fractional shares in reverse/forward split	0	(5,000)
Proceeds from issuance of convertible note	0	3,500,000
Payments for convertible note issuance costs	0	(372,000)
Proceeds from exercise of warrants	3,197,000	0
Net cash provided by financing activities	3,197,000	3,123,000
Effects of exchange rates on cash and cash equivalents	0	81,000
Net change in cash and cash equivalents	1,606,000	1,160,000
Cash and cash equivalents, beginning of period	3,443,000	3,704,000
Cash and cash equivalents, end of period	5,049,000	4,864,000
Supplemental cash disclosures:
Cash paid for interest	0	23,000
Supplemental disclosures of non-cash investing and financing activities:
Stock issued for services in connection with issuance of convertible note	0	315,000
Warrants issued in connection with issuance of convertible note	0	500,000
Beneficial conversion on convertible note	0	500,000
Intangible asset contributed by non-controlling interest	192,000	862,000
Warrants issued in connection with acquisition of intangible assets	0	851,000
Series A Convertible Preferred Stock, dividends paid in kind	69,000	0
Stock issued for purchase of Medicsight Ltd ordinary shares	0	141,000
Stock issuance for exercise of warrants	440,000	0
Assets acquired and liabilities assumed through purchase of assets:
Prepaid expenses and other current assets	27,000	0
Security deposit	2,000	0
Property and equipment	32,000	0
Intangible assets	632,000	0
Goodwill	4,948,000	0
Other payables	(119,000)	0
Long-term debt	(100,000)	0
JS [Member]
Cash flows from investing activities:
Purchase of intangible assets	0	(200,000)
Supplemental disclosures of non-cash investing and financing activities:
Reclassification of derivative liability	1,164,000	0
FanTD LLC [Member]
Cash flows from investing activities:
Cash paid for purchase of FanTD, LLC, net	(124,000)	0
Supplemental disclosures of non-cash investing and financing activities:
Stock issued for acquistion	3,018,000	0
Fantasy Sports Live [Member]
Cash flows from investing activities:
Purchase of intangible assets	(30,000)	0
Digital Angel Corporation [Member]
Cash flows from investing activities:
Purchase of intangible assets	(136,000)	0
Supplemental disclosures of non-cash investing and financing activities:
Stock issued for acquistion	202,000	0
Daily Joust [Member]
Cash flows from investing activities:
Purchase of intangible assets	(50,000)	0
Medicsight Ltd [Member]
Cash flows from investing activities:
Purchase of Medicsight Ltd shares	0	(14,000)
Preferred Series A Warrants [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	598,000	0
Supplemental disclosures of non-cash investing and financing activities:
Reclassification of derivative liability	8,206,000	0
Series A Warrants [Member]
Supplemental disclosures of non-cash investing and financing activities:
Stock issuance for exercise of warrants	$ 2,761,000	$ 0